de Sá Bianca Costa Soares, Fugimori Melissa Lissae, Ribeiro Karina de Cássia Braga, Duprat Neto João Pedreira, Neves Rogério Izar, Landman Gilles
Department of Skin Oncology, Hospital AC Camargo, São Paulo, Brazil.
Melanoma Res. 2009 Jun;19(3):135-41. doi: 10.1097/CMR.0b013e32831993f3.
Cutaneous melanoma is one of the leading causes of cancer-related death. Malignant transformation of epidermal melanocytes is a multifactorial process involving cell cycle and death control pathways. The purpose of this study was to analyze the immunohistochemical expression of cell-cycle-related and apoptosis-related proteins in cutaneous superficial spreading melanomas using the tissue microarray technique to further understand tumor development. A total of 20 samples of in-situ melanomas and 44 melanomas <or=1.0 mm were analyzed in conventional sections whereas 72 melanomas greater than 1.0 mm and 29 metastases were evaluated by tissue microarray. The sections were stained for the following proteins: p16INK4 (p16), cyclin D1, cyclin-dependent kinase 4 (Cdk4), retinoblastoma protein, tumor suppressor protein p53, and p21 cell cycle regulator (p21) using a streptavidine-biotin-peroxidase technique for immunohistochemistry. Thick melanomas (>1.0 mm) and metastases lost p16 expression in 100% of the cases and in-situ and thin melanomas (<or=1.0 mm) had low rate of p16 expression (7.9%). When comparing thin versus thick melanomas, thin melanomas showed higher expression of cyclin D1 and cytoplasmatic Cdk4, and thick melanomas had increased expression of nuclear Cdk4, tumor suppressor protein p53, and p21. Primary tumors, when compared with metastases, had higher cytoplasmatic Cdk4 expression. None of the studied proteins influenced overall or disease-free survival. Our results suggest that loss of p16 expression was a constant feature in primary and metastatic melanomas. Cyclin D1 expression seems to be related to initial phases of melanoma development. An increase in p21 expression could represent a cell cycle control in proliferating cells with reduced p16 and/or increased nuclear Cdk4 expression.
皮肤黑色素瘤是癌症相关死亡的主要原因之一。表皮黑素细胞的恶性转化是一个多因素过程,涉及细胞周期和死亡控制途径。本研究的目的是使用组织芯片技术分析皮肤浅表扩散性黑色素瘤中细胞周期相关蛋白和凋亡相关蛋白的免疫组化表达,以进一步了解肿瘤的发展。在常规切片中分析了20例原位黑色素瘤样本和44例厚度≤1.0 mm的黑色素瘤,而通过组织芯片评估了72例厚度大于1.0 mm的黑色素瘤和29例转移灶。使用链霉亲和素-生物素-过氧化物酶技术对切片进行以下蛋白质染色:p16INK4(p16)、细胞周期蛋白D1、细胞周期蛋白依赖性激酶4(Cdk4)、视网膜母细胞瘤蛋白、肿瘤抑制蛋白p53和p21细胞周期调节因子(p21),用于免疫组化。厚黑色素瘤(>1.0 mm)和转移灶在100%的病例中p16表达缺失,原位和薄黑色素瘤(≤1.0 mm)p16表达率较低(7.9%)。比较薄黑色素瘤和厚黑色素瘤时,薄黑色素瘤显示细胞周期蛋白D1和细胞质Cdk4表达较高,厚黑色素瘤中核Cdk4、肿瘤抑制蛋白p53和p21表达增加。与转移灶相比,原发性肿瘤细胞质Cdk4表达较高。所研究的蛋白质均未影响总生存期或无病生存期。我们的结果表明,p16表达缺失是原发性和转移性黑色素瘤的一个恒定特征。细胞周期蛋白D1表达似乎与黑色素瘤发展的初始阶段有关。p21表达增加可能代表p16降低和/或核Cdk4表达增加的增殖细胞中的细胞周期控制。